

KURZPROTOKOLL
Cassiope

Öffentlicher Titel	Nicht-interventionelle Studie zu Cabozantinib bei fortgeschrittenem Nierenzellkarzinom
Wissenschaftl. Titel	Prospective Non Interventional Study of Cabozantinib Tablets in Adults With Advanced Renal Cell Carcinoma Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy
Kurztitel	Cassiope
Studienart	multizentrisch, Anwendungsbeobachtung, prospektiv, offen/unverblindet, einarmig, Pharma-Studie
Studienphase	nicht zutreffend
Erkrankung	Niere/Harnwege: Nierenzellkrebs: Zweitlinie oder höher
Einschlusskriterien	- Age $\geq$ 18 years old - Has a diagnosis of advanced RCC - Has received at least one prior VEGF-targeted therapy - For whom the treating physician has decided to start treatment with cabozantinib tablets prior to inclusion - No previous exposure to cabozantinib prior to inclusion - Not concurrently involved in an interventional study - Consents to participate in this noninterventional study
Ausschlusskriterien	- There are no exclusion criteria for this study
Alter	18 Jahre und älter
Prüfzentren	Urologie (Rekrutierung beendet) Theodor-Stern-Kai 7 60590 Frankfurt am Main Dr. med. Severine Banek Tel: 069 6301-80072 Fax: 069 6301-84029 severine.banek@unimedizin-ffm.de
Sponsor	Ipsen Pharma
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT03419572 (primäres Register)